Advertisement
Screener

KIORA PHARMACEUTICALS, INC. (KPRX) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate

1.4 / 5 stars · 22/76 Roast Me

KIORA PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate

KIORA PHARMACEUTICALS, INC. (KPRX) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate of 0.00% for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.

Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate · last filed 2026-08-07

  • KIORA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2026-03-31 was 0.00%.
  • KIORA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2024-03-31 was 0.00%.
  • KIORA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2023-03-31 was 0.00%.
  • KIORA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2022-03-31 was 0.00%.
  • KIORA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2025 was 0.00%.
  • KIORA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2024 was 0.00%.
  • KIORA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2023 was 0.00%.
  • KIORA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2022 was 0.00%.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 6 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 9 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 12 month
2026-06-300.00%
10-Q · filed 2026-08-07
2026-03-310.00%
10-Q · filed 2026-05-08
2025-12-310.00%
10-K · filed 2026-03-25
2025-09-300.00%
10-Q · filed 2025-11-07
2025-06-300.00%
10-Q · filed 2026-08-07
2024-12-310.00%
10-K · filed 2026-03-25
2024-09-300.00%
10-Q · filed 2025-11-07
2024-06-300.00%
10-Q · filed 2025-08-08
2024-03-310.00%
10-Q · filed 2024-05-10
2023-12-310.00%
10-K · filed 2025-03-25
2023-09-300.00%
10-Q · filed 2024-11-08
2023-06-300.00%
10-Q · filed 2024-08-09
2023-03-310.00%
10-Q · filed 2024-05-10
2022-12-310.00%
10-K · filed 2024-03-25
2022-09-300.00%
10-Q · filed 2023-11-09
2022-06-300.00%
10-Q · filed 2023-08-08
2022-03-310.00%
10-Q · filed 2023-05-09
2021-12-310.00%
10-K · filed 2023-03-23
2021-09-300.00%
10-Q · filed 2021-11-15
2021-06-300.00%
10-Q · filed 2021-08-12
2021-03-310.00%
10-Q · filed 2021-05-12
2020-12-310.00%
10-K/A · filed 2022-07-07
2020-09-300.00%
10-Q · filed 2021-11-15
2020-06-300.00%
10-Q · filed 2021-08-12
2020-03-310.00%
10-Q · filed 2021-05-12
2019-12-310.00%
10-K · filed 2021-03-25
2019-09-300.00%
10-Q · filed 2020-11-09
2019-06-300.00%
10-Q · filed 2020-08-06
2019-03-310.00%
10-Q · filed 2020-05-06
2018-12-310.00%
10-K · filed 2020-03-04
2018-09-300.00%
10-Q · filed 2019-11-07
2018-06-300.00%
10-Q · filed 2019-08-08
2018-03-310.00%
10-Q · filed 2019-05-08
2017-12-310.00%
10-K · filed 2019-03-01
2017-09-300.00%
10-Q · filed 2018-11-13
2017-06-300.00%
10-Q · filed 2018-08-03
2017-03-310.00%
10-Q · filed 2018-05-11
2016-12-310.00%
10-K · filed 2018-03-02
2016-09-300.00%
10-Q · filed 2017-11-14
2016-06-300.00%
10-Q · filed 2017-08-04
2016-03-310.00%
10-Q · filed 2017-05-05

Similar stocks

Stock NameCountryMarket CapPE Ratio
Scienture Holdings, Inc. (SCNX)United States$0.012B-0.38
Phio Pharmaceuticals Corp. (PHIO)United States$0.012B-0.92
ADIAL PHARMACEUTICALS, INC. (ADIL)United States$0.012B
Dare Bioscience, Inc. (DARE)United States$0.011B
BIOVIE INC. (BIVI)United States$0.012B
Aspire Biopharma Holdings, Inc. (ASBP)United States$0.012B-0.60
Tempest Therapeutics, Inc. (TPST)United States$0.013B
Moleculin Biotech, Inc. (MBRX)United States$0.011B
MetaVia Inc. (MTVA)United States$0.011B-0.65
KALA BIO, Inc. (KALA)United States$0.011B-3.33